OLMA Olema Pharmaceuticals Inc.

39.92
-1.71  -4%
Previous Close 41.63
Open 41.69
52 Week Low 35.73
52 Week High 60.27
Market Cap $1,603,575,941
Shares 40,169,738
Float 27,409,024
Enterprise Value $1,632,413,919
Volume 121,517
Av. Daily Volume 92,102
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
OP-1250
HR+, HER2- Breast Cancer
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Latest News

  1. SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will participate at the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference
    Date and Time: March 2, 2021 at 2:10 p.m. Eastern Time
    Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.

    33rd Annual ROTH Growth Conference
    Date and Time: March 15, 2021 at 5:00 p.m. Eastern Time
    Sean P. Bohen, M.D., Ph.D., President and Chief…

    SAN FRANCISCO, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that it will participate at the following upcoming virtual investor conferences:

    Cowen 41st Annual Health Care Conference

    Date and Time: March 2, 2021 at 2:10 p.m. Eastern Time

    Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual breast cancer panel discussion.

    33rd Annual ROTH Growth Conference

    Date and Time: March 15, 2021 at 5:00 p.m. Eastern Time

    Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema, is scheduled to participate in a virtual women's health panel discussion.

    About Olema Oncology

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

    Contacts

    Investor Contact:

    Media Contact:

    Sheryl Seapy, W2O



    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  2. SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time.

    The presentation and Q&A session will be webcast live from the Investors & Media section of Olema's website. A replay of the webcast will be available.

    About Olema Oncology
    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development…

    SAN FRANCISCO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced that Sean P. Bohen, M.D., Ph.D., president and chief executive officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Monday, January 11, 2021, at 10 a.m. Eastern Time.

    The presentation and Q&A session will be webcast live from the Investors & Media section of Olema's website. A replay of the webcast will be available.

    About Olema Oncology

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

    Contacts

    Investor Contact:

    Media Contact:

    Sheryl Seapy, W2O



    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  3. SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.

    The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy…

    SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.

    The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2 negative (HER2-) breast cancer.

    The accepted abstracts are now available online through the SABCS conference website. Details are as follows:

    Olema Poster Presentations

    Session: 18 – Tumor Biology III

    Poster #: PS18-16

    Abstract #: 1410

    Title: The Complete Estrogen Receptor Antagonist OP-1250 Shrinks Tumors in Xenograft Models and Has Favorable Preclinical Pharmacokinetic Attributes

    Session Date & Time: Wednesday, December 9, 2020; 8:00 a.m. CT

    Session: Ongoing Trials – Endocrine Therapy

    Poster #: OT-09-10

    Abstract #: 1167

    Title: A Phase I/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects

    with Locally Advanced, Recurrent, and Metastatic Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer

    Session Date & Time: Wednesday, December 9, 2020; 8:00 a.m. CT

    About Olema Oncology

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

    Forward Looking Statements

    Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "believe," "anticipate," "plan," "expect," "intend," "will," "may," "goal," "project," "estimate," "potential" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential safety, functional characteristics and efficacy of OP-1250; and Olema's ability to successfully advance, and the potential timelines for, the development of OP-1250. Because such statements deal with future events and are based on Olema's current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema's ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the sections titled "Risk Factors" in Olema's prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on November 19, 2020, and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

    Contacts

    Investor Contact:

     

    Media Contact:

    Sheryl Seapy, W2O

     

    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  4. SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Olema Oncology from the offering were approximately $240.4 million, before deducting the underwriting discounts and commissions…

    SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced the closing of its previously announced initial public offering of 12,650,000 shares of its common stock, which includes 1,650,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Olema Oncology from the offering were approximately $240.4 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Select Market on November 19, 2020, under the ticker symbol "OLMA."

    J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC acted as active joint book-running managers for the offering. Canaccord Genuity LLC also acted as a book-running manager.

    Registration statements relating to these securities were filed with the U.S. Securities and Exchange Commission (SEC) and became effective on November 18, 2020. Copies of the registration statements can be accessed through the SEC's website at www.sec.gov. This offering was made only by means of a written prospectus, forming a part of the effective registration statements. Copies of the final prospectus relating to the initial public offering can be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (212) 834-4533 or by email at ; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at ; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at +1 (833) 297-2926 or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    About Olema Oncology

    Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.

    Contacts

    Investor Contact:

    Media Contact:

    Sheryl Seapy, W2O



    949-903-4750

     



    Primary Logo

    View Full Article Hide Full Article
View All Olema Pharmaceuticals Inc. News